Association between Treatment for Localized Prostate Cancer and Mental Health Outcomes

J Urol. 2022 May;207(5):1029-1037. doi: 10.1097/JU.0000000000002370. Epub 2022 Mar 3.

Abstract

Purpose: We aimed to compare patient-reported mental health outcomes for men undergoing treatment for localized prostate cancer longitudinally over 5 years.

Materials and methods: We conducted a prospective population-based analysis using the Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) study. Patient-reported depressive symptoms (Centers for Epidemiologic Studies Depression [CES-D]) and domains of the Medical Outcomes Study 36-item Short Form survey evaluating emotional well-being and energy/fatigue were assessed through 5 years after treatment with surgery, radiotherapy (with or without androgen deprivation therapy) and active surveillance. Regression models were adjusted for outcome-specific baseline function, demographic and clinicopathological characteristics, and treatment approach.

Results: A total of 2,742 men (median [quartiles] age 64 [59-70]) met inclusion criteria. Baseline depressive symptoms, as measured by the CES-D, were low (median 4, quartiles 1-8) without differences between groups. We found no effect of treatment modality on depressive symptoms (p=0.78), though older age, poorer health, being unmarried and baseline CES-D score were associated with declines in mental health. There was no clinically meaningful association between treatment modality and scores for either emotional well-being (p=0.81) or energy/fatigue (p=0.054).

Conclusions: This prospective, population-based cohort study of men with localized prostate cancer showed no clinically important differences in mental health outcomes including depressive symptoms, emotional well-being, and energy/fatigue according to the treatment received (surgery, radiotherapy, or surveillance). However, we identified a number of characteristics associated with worse mental health outcomes including: older age, poorer health, being unmarried, and baseline CES-D score which may allow for early identification of patients most at risk of these outcomes following treatment.

Keywords: mental health; prostatic neoplasms; quality of life.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Androgen Antagonists* / adverse effects
  • Cohort Studies
  • Fatigue / chemically induced
  • Fatigue / etiology
  • Humans
  • Male
  • Middle Aged
  • Patient Reported Outcome Measures
  • Prospective Studies
  • Prostatic Neoplasms* / pathology
  • Quality of Life

Substances

  • Androgen Antagonists